Article Contents ::
- 1 The Brand Name DUKINASE Has Generic Salt :: Urokinase
- 2 DUKINASE Is From Company Samarth Priced :: Rs. 3550
- 3 DUKINASE have Urokinase is comes under Sub class Thrombolytics of Main Class Hematological System
- 4 Main Medicine Class:: Hematological System Sub Medicine Class :: Thrombolytics
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name DUKINASE Has Generic Salt :: Urokinase
DUKINASE Is From Company Samarth Priced :: Rs. 3550
DUKINASE have Urokinase is comes under Sub class Thrombolytics of Main Class Hematological System
Main Medicine Class:: Hematological System Sub Medicine Class :: Thrombolytics
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Acute MI, Pulmonary embolism, Thromboembolism, Deep vein thrombosis
Drug Dose ::
Adult: IV Deep vein thrombosis; Pulmonary embolism Initial: 4,400 u/kg over 10 mins, then 4,400 u/kg/hr for 12-24 hr (deep vein thrombosis) or 12 hr (pulmonary embolism). Acute MI 2-3 million u as infusion. Peripheral arterial thromboembolism As 2,000 u/ml soln: Infuse into a clot via a catheter at a rate of 4,000 u/min for 2 hr. Monitor response using angiography. If clot is not removed, the catheter is advanced into the occluded vessel and continue infusion for another 2 hr. May repeat procedure up to 4 times if needed. If blood flow is re-established, partially remove cathether and infuse at 1,000 u/min till remaining clot has lysed. Inj Clearance of occluded catheters and shunts Instill 5,000 – 25,000 u into affected IV catheter or shunt and clamped for up to 4 hr. Aspirate the lysate and repeat the procedure if needed. Irrigation Break down of clots in hyphaema Dissolve 5,000 u in 2 mL of sterile distilled water. Irrigate the anterior chamber with 0.3 mL of the prepared soln and leave it in situ for 3 mins before washing out w/ saline. Repeat 5 times. May leave 0.3 mL in the anterior chamber for 24-48 hr if residual clot is still present at the end.
Active internal bleeding; history of cerebrovascular accident; recent (within 2 mth) trauma of any kind including surgery; aneurysm; known bleeding diathesis; severe uncontrolled hypertension. Recent history of peptic ulcer disease, oesophageal varices, ulcerative colitis or other bleeding GI lesions; pancreatitis; subacute bacterial endocarditis; coagulation defects including those due to liver or kidney disease, or after recent surgery, childbirth or trauma. Increased risk of cerebral bleeding e.g. recent stroke or cerebral neoplasm. Pregnancy.
Drug Precautions ::
Any vascular punctures or invasive procedures should be avoided as far as possible during, and immediately before and after urokinase therapy and if unavoidable done with great care. External chest compression. Caution in conditions eg, possibility of left heart thrombus, subacute bacterial endocarditis, coagulation defects, cerebrovascular disease, diabetic retinopathy and any conditions in which bleeding could be dangerous. Monitor for reperfusion arrhythmias when used in MI.
Drug Side Effects ::
Bleeding, pyrexia, haematuria, thromboembolic episodes, hypersensitivity reactions. Potentially Fatal: Severe bleeding, anaphylaxis.
Pregnancy category ::
Drug Mode of Action ::
Urokinase, an enzyme isolated from human urine, directly converts plasminogen into plasmin, which is a proteolytic enzyme with fibrinolytic effects. It is a fibrin non-specific thrombolytic as it affects both unbound and fibrin bound plasminogen.
Drug Interactions ::
Reduced thrombolytic effect when given again some time later due to development of high levels of antibodies. Potentially Fatal: Platelet inhibitors eg, aspirin and indometacin can potentiate the action of urokinase and cause haemorrhage. Heparin and oral anticoagulants may increase risk of bleeding.